About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

OncoTherapy Science, Inc.(4564) Summary

4564
TSE Growth
OncoTherapy Science, Inc.
24
JPY
-2
(-7.69%)
Apr 4, 3:30 pm JST
0.16
USD
Apr 4, 2:30 am EDT
Result
PTS
outside of trading hours
24.3
Apr 4, 3:49 pm JST
Summary Chart Historical News Financial Result
PER
PBR
8.63
Yield
ー%
Margin Trading Ratio
4.45
Stock Price
Apr 4, 2025
Opening Apr 4, 9:00 am
25 JPY 0.17 USD
Previous Close Apr 3
26 JPY 0.17 USD
High Apr 4, 9:00 am
25 JPY 0.17 USD
Low Apr 4, 1:37 pm
23 JPY 0.15 USD
Volume
3,334,800
Trading Value
0.08B JPY 0.55M USD
VWAP
24.24 JPY 0.17 USD
Minimum Trading Value
2,400 JPY 16 USD
Market Cap
6.52B JPY 0.04B USD
Number of Trades
343
Liquidity & Number of Trades
As of Apr 4, 2025
Liquidity
Slightly High
1-Year Average
549
1-Year High Aug 1, 2024
5,463
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 28, 2025 3,002,900 13,366,100 4.45
Mar 21, 2025 3,082,100 13,349,000 4.33
Mar 14, 2025 3,028,600 13,616,200 4.50
Mar 7, 2025 3,017,800 13,593,300 4.50
Feb 28, 2025 3,089,800 14,079,300 4.56
Company Profile
OncoTherapy Science, Inc. is a drug discovery venture originating from the Institute of Medical Science at the University of Tokyo. The company's main focus is on cancer gene analysis and the development of cancer therapeutics.
Sector
Pharmaceuticals
OncoTherapy Science, Inc. is a research and development-oriented venture that broadly engages in cancer drug development, from drug discovery research to clinical trials. The company promotes R&D in various areas including small molecule drugs, cancer peptide vaccines, and antibody drugs, with multiple ongoing clinical trials. Through its subsidiary, OncoTherapy Science also conducts large-scale cancer gene analysis tests and research and development of cancer immunotherapy, thus engaging in cancer precision medicine-related businesses. The company aims to realize personalized medicine through these efforts. OncoTherapy Science has established a staged revenue model including upfront payments, milestones, and royalties through partnerships with major pharmaceutical companies. The company is characterized by its long-term approach to research and development. As a result, its financial performance largely depends on the development progress of partnering pharmaceutical companies and the sales status of pharmaceuticals, which may not be reflected in short-term results in many cases.